quinazolines has been researched along with Biliary Tract Cancer in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (39.29) | 29.6817 |
| 2010's | 16 (57.14) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Toubah, TE; Cao, B; Centeno, BA; Kim, J; Kim, RD; Mehta, R; Tan, ES | 1 |
| Ajavon-Hartmann, A; Alberts, SR; Genvresse, I; Grilley-Olson, JE; Kelly, A; Kim, RD; Peña, C; Xia, C | 1 |
| Abdel-Rahman, O; Elhalawani, H; Elsayed, Z | 1 |
| Anthoney, A; Backen, AC; Beare, S; Bridgewater, JA; Corrie, PG; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; McNamara, MG; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Choi, DW; Choi, JY; Choi, MK; Choi, SH; Heo, JS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, YS | 1 |
| Arrivas Bajardi, E; Barone, C; Bencardino, K; Buonadonna, A; Cartenì, G; Comandone, A; Ferrari, D; Ferrari, S; Foa, P; Gebbia, V; Milella, M; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Testa, A; Tronconi, MC; Zaniboni, A | 1 |
| Anthoney, DA; Backen, AC; Beare, S; Bridgewater, JA; Corrie, P; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; Morris, K; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C | 1 |
| Belani, CP; Dancey, J; Gandara, DR; Gandour-Edwards, R; Iqbal, S; Kindler, HL; Lenz, HJ; Longmate, J; Lurje, G; Mack, PC; Ramanathan, RK; Singh, DA; Tanaka, M; Yen, Y | 1 |
| Berger, W; Brandstetter, A; Filipits, M; Gruenberger, T; Herberger, B; Novak, S; Pirker, C; Puhalla, H; Schmid, K | 1 |
| Erlichman, CE; Holen, KD; Horvath, L; Kim, GP; Kolesar, JL; Loconte, NK; Lubner, SJ; Mahoney, MR; Philip, PA; Picus, J; Pitot, HC; Van Hazel, G; Yong, WP | 1 |
| Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Jensen, LH | 1 |
| Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM | 1 |
| Bufill, JA; Chiorean, EG; Coleman, N; Currie, C; Johnston, EL; Loehrer, PJ; Picus, J; Ramasubbaiah, R; Tong, Y; Yu, M | 1 |
| Faris, JE; Zhu, AX | 1 |
| Bekaii-Saab, T; O'Neil, B; Peck, J; Villalona Calero, M; Wei, L; Zalupski, M | 1 |
| Aglietta, M; Cavalloni, G; Gammaitoni, L; Leone, F; Marchiò, S; Migliardi, G; Peraldo-Neia, C; Sarotto, I; Soster, M | 1 |
| Amoroso, V; Ferrari, VD; Fusi, A; Mambrini, A; Marini, G; Marpicati, P; Montini, E; Rangoni, G; Simoncini, E; Valcamonico, F; Vasalli, L | 1 |
| Baker, SD; Hartke, C; He, P; Hidalgo, M; Jimeno, A; Li, J; Zabelina, Y; Zhao, M | 1 |
| Amador, ML; Bouraoud, N; Hidalgo, M; Jimeno, A; Kulesza, P; Maitra, A; Oppenheimer, D; Rubio-Viqueira, B; Sebastiani, V | 1 |
| Barthélemy, P; Bennouna, J; Bourgeois, H; Dorval, E; Douillard, JY; François, E; Hebbar, M; Martin, C; Mayeur, D; Perrier, H | 1 |
| Allmer, C; Donehower, RC; Erlichman, C; Fitch, T; Kim, G; Mahoney, MR; Philip, PA; Picus, J; Pitot, HC; Thomas, J | 1 |
| Blüthner, T; Caca, K; Feisthammel, J; Kamenz, T; Kluge, A; Mössner, J; Tannapfel, A; Wiedmann, M | 1 |
| Amador, ML; Grunwald, V; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Rubio-Viqueira, B | 1 |
| Albert, D; Brock, K; Chick, J; Ciuleanu, T; Diculescu, M; Herrmann, T; Hoepffner, NM; Philip, PA; Roth, A; Sailer, V; Trojan, J; Zalupski, M | 1 |
| Aglietta, M; Cavalloni, G; Leone, F; Pignochino, Y | 1 |
3 review(s) available for quinazolines and Biliary Tract Cancer
| Article | Year |
|---|---|
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur | 2018 |
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2011 |
Targeted therapy for biliary tract cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Gallbladder Neoplasms; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Panitumumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
17 trial(s) available for quinazolines and Biliary Tract Cancer
| Article | Year |
|---|---|
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Progression-Free Survival; PTEN Phosphohydrolase; Pyrimidines; Quinazolines | 2021 |
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Treatment Outcome | 2018 |
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Keratin-18; Male; Middle Aged; Neoplasm Proteins; Neoplastic Cells, Circulating; Quinazolines; Treatment Outcome; United Kingdom; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2015 |
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; United Kingdom | 2015 |
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome | 2016 |
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Humans; Lapatinib; Liver Neoplasms; Quinazolines; Survival Analysis | 2009 |
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Cholangiocarcinoma; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cadherins; Carcinoma, Hepatocellular; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2012 |
HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2012 |
Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Epirubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Survival Analysis; Thiophenes | 2004 |
A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Quinazolines; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2005 |
Phase II study of erlotinib in patients with advanced biliary cancer.
Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2006 |
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Female; Fluorouracil; Glutarates; Humans; Isoindoles; Leucovorin; Male; Middle Aged; Quinazolines; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2007 |
8 other study(ies) available for quinazolines and Biliary Tract Cancer
| Article | Year |
|---|---|
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biliary Tract Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinases; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
Biliary-tract cancer: improving therapy by adding molecularly targeted agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Topics: Aged; Animals; Antineoplastic Agents; Benzodioxoles; Biliary Tract Neoplasms; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Phosphorylation; Quinazolines; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.
Topics: Animals; Biliary Tract Neoplasms; Chromatography, High Pressure Liquid; Drug Stability; ErbB Receptors; Female; Gefitinib; Humans; Liver; Mass Spectrometry; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Skin | 2005 |
Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cell Line, Tumor; Cetuximab; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunohistochemistry; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transfection | 2005 |
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Topics: Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; DNA, Complementary; DNA, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Purines; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2007 |
Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Research Design; Treatment Outcome | 2007 |